Sen. Tillis aims to release draft resolving Clarity Act's stablecoin yield dispute this week: report
U.S. Senator Thom Tillis (R-N.C.) said that he hopes to release a draft agreement this week to resolve the ongoing stablecoin yield dispute between banks and crypto firms, according to a Monday report from Politico.
Tillis has reportedly been working with Sen. Angela Alsobrooks (D-Md.) to develop language in the Clarity Act to end the long-standing debate on whether cryptocurrency companies should be allowed to pay interest on idle stablecoin balances.
"I think the language has come together well," Tillis told Politico on Monday, adding that the text may be publicly released later this week if discussions proceed smoothly.
The latest draft proposal from Tillis and Alsobrooks has been viewed by both banking and crypto representatives, and has drawn pushback from banks, according to the report, though the source of the criticism is unclear. Tillis reportedly indicated that he is willing to make further changes.
The debate over stablecoin rewards has become the most contentious issue in the Clarity Act, a long-sought bill to establish comprehensive rules for the digital asset sector. While the GENIUS Act, passed last year, stipulates that stablecoin issuers are banned from paying interest to holders, it does not ban third-party platforms, such as exchanges, from offering yield.
U.S. banks have argued that allowing such rewards would cause a major structural disruption, draining significant deposits away from traditional institutions. Crypto firms, namely Coinbase, have maintained that banning such rewards will stifle innovation and argued that it could provide new business opportunities for banks, not just crypto entities.
Since the beginning of the year, the White House has convened several closed-door meetings to facilitate a resolution, but no agreement has been reached as the two parties remain fixed in their positions.
The Clarity Act has a long way to go, even if banks and crypto firms land on an agreement. It has yet to pass a vote in the Senate Banking Committee, after which it will have to be reconciled with the Senate Agriculture Committee before going to a full floor vote.
Meanwhile, Senator Tillis also reportedly mentioned a possibility of a "crypto-palooza" to invite both banking and crypto representatives to Capitol Hill to discuss the stablecoin yield matter and resolve the standoff.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
